33 related articles for article (PubMed ID: 6616494)
1. Advantages of integrated trials for performing multiple Phase II studies.
Weiss GB; Hokanson JA
Invest New Drugs; 1984; 2(4):409-14. PubMed ID: 6511244
[TBL] [Abstract][Full Text] [Related]
2. Ethical issues in cooperative cancer therapy trials from a statistical viewpoint. II. Specific issues.
Shuster JJ; Krischer JP; Boyett JM
Am J Pediatr Hematol Oncol; 1985; 7(1):64-70. PubMed ID: 4037245
[TBL] [Abstract][Full Text] [Related]
3. Confidence limits for probability of response in multistage phase II clinical trials.
Atkinson EN; Brown BW
Biometrics; 1985 Sep; 41(3):741-4. PubMed ID: 4074823
[TBL] [Abstract][Full Text] [Related]
4. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
5. Selection designs for pilot studies based on survival.
Liu PY; Dahlberg S; Crowley J
Biometrics; 1993 Jun; 49(2):391-8. PubMed ID: 8369375
[TBL] [Abstract][Full Text] [Related]
6. Practical side of multistage clinical trials for screening new agents.
Herson J
Cancer Treat Rep; 1983 Jan; 67(1):71-5. PubMed ID: 6616494
[TBL] [Abstract][Full Text] [Related]
7. How large should a phase II trial of a new drug be?
Simon R
Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
[TBL] [Abstract][Full Text] [Related]
8. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
9. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
10. Futility approaches to interim monitoring by data monitoring committees.
Demets DL
Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
[TBL] [Abstract][Full Text] [Related]
11. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
